Conscious-3: A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Clazosentan in Reducing Vasospam-related Morbidity and All-Cause Mortality in Adult Patients